Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Sarcoma, Kaposi × Etoposide × Clear all

Phase

Phase 2 2 Phase 3 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Lymphoma 33 Leukemia 32 Small Cell Lung Carcinoma 30 Leukemia, Myeloid, Acute 24 Precursor Cell Lymphoblastic Leukemia-Lymphoma 23 Lung Neoplasms 22 Lymphoma, Large B-Cell, Diffuse 17 Neuroblastoma 14 Lymphoma, Non-Hodgkin 13 Hodgkin Disease 13 Leukemia, Erythroblastic, Acute 12 Carcinoma, Non-Small-Cell Lung 12 Leukemia, Myelomonocytic, Acute 11 Leukemia, Monocytic, Acute 11 Leukemia, Megakaryoblastic, Acute 11 Sarcoma 10 Lymphoma, Follicular 9 Burkitt Lymphoma 9 Lymphoma, Large-Cell, Immunoblastic 8 Myelodysplastic Syndromes 7 Testicular Neoplasms 6 Teratoma 6 Congenital Abnormalities 6 Anemia, Refractory, with Excess of Blasts 6 Endodermal Sinus Tumor 5 Central Nervous System Neoplasms 5 Testicular Germ Cell Tumor 4 Rhabdomyosarcoma 4 Parkinson Disease 4, Autosomal Dominant Lewy Body 4 Neuroectodermal Tumors, Primitive, Peripheral 4

Interventions

Doxorubicin 5 Liposomes 4 Vincristine 3 Bleomycin 3 liposomal doxorubicin 1 Paclitaxel 1 Etoposide 1 Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination 1 Daunorubicin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01352117 2019-11-14

REACT-KS

Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections

Phase 3 Completed

192 enrolled 35 charts

Sarcoma, Kaposi

Data powered by HemOnc (CC BY 4.0) Colophon ⚡